MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Takes Position in Insulet Co. (NASDAQ:PODD)

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH bought a new stake in shares of Insulet Co. (NASDAQ:PODD) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,337 shares of the medical instruments supplier’s stock, valued at approximately $1,402,000.

Several other hedge funds have also recently made changes to their positions in PODD. Empowered Funds LLC raised its position in shares of Insulet by 357.4% during the 4th quarter. Empowered Funds LLC now owns 4,327 shares of the medical instruments supplier’s stock valued at $1,130,000 after buying an additional 3,381 shares in the last quarter. Asset Management One Co. Ltd. raised its position in Insulet by 2.3% in the 4th quarter. Asset Management One Co. Ltd. now owns 26,766 shares of the medical instruments supplier’s stock worth $7,096,000 after purchasing an additional 605 shares during the period. Vontobel Holding Ltd. raised its position in Insulet by 4.3% in the 4th quarter. Vontobel Holding Ltd. now owns 2,423 shares of the medical instruments supplier’s stock worth $633,000 after purchasing an additional 100 shares during the period. Banque Pictet & Cie SA purchased a new stake in Insulet in the 4th quarter worth about $287,000. Finally, Valeo Financial Advisors LLC purchased a new stake in Insulet in the 4th quarter worth about $208,000.

Insider Buying and Selling at Insulet

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the firm’s stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the sale, the director now directly owns 3,231 shares in the company, valued at $888,525. This trade represents a 36.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the sale, the senior vice president now owns 23,180 shares of the company’s stock, valued at $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is owned by insiders.

Insulet Price Performance

NASDAQ PODD opened at $304.63 on Monday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The firm’s 50 day moving average price is $287.15 and its 200-day moving average price is $275.06. Insulet Co. has a 52-week low of $173.00 and a 52-week high of $329.33. The company has a market cap of $21.44 billion, a PE ratio of 52.61, a P/E/G ratio of 3.62 and a beta of 1.37.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.21. The firm had revenue of $569.00 million for the quarter, compared to the consensus estimate of $543.20 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company’s quarterly revenue was up 28.8% on a year-over-year basis. During the same period last year, the firm earned $0.73 earnings per share. Sell-side analysts forecast that Insulet Co. will post 3.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on PODD. The Goldman Sachs Group began coverage on shares of Insulet in a research report on Friday, May 30th. They issued a “buy” rating and a $380.00 price objective on the stock. Barclays increased their price objective on shares of Insulet from $234.00 to $266.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 30th. Wolfe Research raised shares of Insulet from a “peer perform” rating to an “outperform” rating and set a $350.00 price objective on the stock in a research report on Tuesday, May 13th. Wells Fargo & Company set a $322.00 price objective on shares of Insulet in a research report on Monday, April 28th. Finally, Sanford C. Bernstein restated an “outperform” rating on shares of Insulet in a research note on Friday, May 16th. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and an average target price of $318.41.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.